Last reviewed 26 August 2026
Between mid-2025 and mid-2026 the American research-peptide market went through the biggest shake-out in its history: criminal convictions, an FDA warehouse raid, a wave of federal warning letters, civil suits from a pharmaceutical giant, and the voluntary closure of some of the largest names in the field. UK buyers who relied on US sites are now searching for what happened, whether the successors are genuine, and what ordering from abroad actually involves. Here is the record, source by source — and it is worth reading even if you never intend to order from the US, because what the enforcement documents reveal about “research use only” labels applies to this whole market.
Every statement here is a statement about a public record; nothing is a statement about any compound, and named businesses are described only by verifiable facts — official actions, court outcomes and their own published notices.
The shake-out, name by name
Paradigm Peptides — criminal conviction. In July 2026 the owner of Paradigm Peptides, which operated until March 2024, was sentenced to 70 months in federal prison; a senior employee received 16 months. Government testing of six products sold as SARM compounds found all of them contained actual testosterone
; the owner admitted the company forged laboratory certificates to lend credibility to their peptides
. The business had roughly 54,000 customers across 80 countries and forfeited $5 million. Sit with the certificates line for a moment: this is why our supplier-verification checklist says a certificate you cannot verify against the issuing laboratory is just a PDF.
Amino Asylum — FDA raid. In June 2025 the FDA raided the warehouse of Amino Asylum, one of the larger US research-peptide sellers, which then went offline; a health-law analysis of the period records that at least seven other research peptide companies closed during 2025 alone
.
Science.bio — voluntary closure. On 27 January 2026 Science.bio announced it was permanently closing
, citing regulatory compliance, stating it would not return and committing to fulfil or refund outstanding orders — the orderly version of a market exit.
Peptide Sciences — closure, reasons unconfirmed. In early March 2026 the best-known name in the US market shut down voluntarily. No official action against it has been published and the reasons remain unconfirmed — worth stating plainly, because the vacuum filled immediately with lookalike sites claiming to be its relaunch. None is a confirmed successor. A displaced customer typing a dead vendor’s name into Google today lands mostly on affiliate pages and unverified claimants; treat every “official relaunch” as unproven.
And the civil front opened. In August 2026 Eli Lilly filed suits in four federal courts against six businesses — research-use-only sellers, a med spa and a compounding pharmacy — over retatrutide sales. The health-law commentary on the filings compresses the lesson into one line: RUO labels provide no legal protection if marketing suggests human use.
What the FDA actually did
Two actions matter, and they point in opposite directions — which is why the market’s reporting of them is so confused.
The warning letters. After issuing more than fifty warning letters to peptide sellers in September 2025, the FDA published another batch on 31 March 2026, and the letters — we have read the full texts — are precise about why the disclaimer fails: Despite statements on your product labeling marketing your products for ‘laboratory research purposes only’ and ‘[n]ot for human consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.
The evidence cited is the sellers’ own benefit copy and dosing charts. One construction in the letters deserves special attention: sellers offering bacteriostatic water alongside injectable peptides were told the sale of these products together demonstrates that you intend for your ‘Bacteriostatic Water’ to be used in combination for injection. Therefore, your ‘Bacteriostatic Water’ is a drug.
The regulator reads the whole shop, not the label — the same doctrine the MHRA and Ireland’s HPRA apply on this side of the Atlantic.
The Category 2 removal. On 15 April 2026 the FDA removed twelve peptides — BPC-157, TB-500, GHK-Cu (injectable), KPV, MOTS-C, Semax, Epitalon, DSIP and others — from Category 2 of its compounding list, the tier reserved for substances the agency has determined raise significant safety concerns
. Grey-market marketing instantly spun this as approval. The legal analyses are unambiguous that it is not: removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A
, and the substances sit in a regulatory grey area pending advisory-committee review. What actually changed is procedural; what did not change is that none of these compounds is an approved medicine anywhere.
What a UK buyer of a US site faces now
Four things, stacking. First, the border: a US parcel is an import into Great Britain, with everything that involves — examination, potential seizure of anything classified as an unauthorised medicine, and the absence of any official postal “personal allowance” — set out with sources in Do research peptides get stopped at UK customs? Second, the charges: import VAT at 20%, customs duty above £135, the carrier’s handling fee, and a parcel that can sit weeks in clearance. Third, the counterparty problem this year made vivid: when a US seller vanishes mid-order, a UK buyer’s realistic remedy is a card chargeback — and much of this market doesn’t take cards. Distance-selling rights that are enforceable against a UK company are, in practice, nearly unenforceable against a foreign one. Fourth, the successor trap: the sites soliciting a dead vendor’s customers are unverified by definition.
The honest takeaway
We are not going to end this with a list of “trusted alternatives” — that is the affiliate grammar this article exists to counterweigh, and every such list is selling you its links. The portable lessons are three. A research-use label protects nobody whose marketing says otherwise — that is now the settled position of the FDA, the MHRA and the HPRA alike, and it is why our copy reads the way it does. A certificate that cannot be verified against the laboratory that issued it is decoration — Paradigm forged theirs for years. And geography is not a detail: stock held in the country you live in removes the border, the charges, the clearance queue and most of the counterparty risk in one move. Whoever you buy from, buy from someone you can actually check.
What this article does not settle
US regulatory positions are moving — advisory-committee reviews are pending and litigation is live — so check the linked documents for the current state. Nothing here is a statement about any compound’s effects, and nothing NovoVita supplies is for human or veterinary use; it is supplied for laboratory research only. This is analysis, not legal advice.
Sources
- CBS News, Peptides seller sentenced (30 July 2026) — the Paradigm Peptides conviction, testing results, forged certificates, customer numbers and forfeiture; the DOJ release is at justice.gov.
- AMC Defense Law, Peptide industry federal criminal charges (24 March 2026) — the Amino Asylum raid, the 2025 closures, the warning-letter wave.
- Rapamycin News forum, Science.bio closes (27 January 2026) — the closure announcement as posted.
- FDA warning letters of 31 March 2026 — Lovega LLC dba Pink Pony Peptides and Gram Peptides; full texts also mirrored by The Partnership for Safe Medicines.
- Frier Levitt, FDA removes 12 peptides from Category 2 (16 April 2026) and Lilly’s retatrutide lawsuits against RUO sellers (18 August 2026); Orrick, analysis of the Category 2 removal.
- Health Law Alliance, FDA targets RUO labeling (8 January 2026) — the September 2025 warning-letter wave.
- GOV.UK, Tax and customs for goods sent from abroad.